title: Fat compartments and apolipoprotein B-100 kinetics in overweight-obese men.
abstract: OBJECTIVE
  To examine the association between the kinetics of very-low-density-lipoprotein (VLDL)-apolipoprotein B-100 (apoB) and intraperitoneal, retroperitoneal, subcutaneous abdominal, and total adipose tissue masses (IPATM, RPATM, SAATM, and TATM, respectively) in overweight/obese men.
  
  
  METHODS
  Hepatic secretion of VLDL was measured using an intravenous infusion of 1-[(13)C]-leucine in 51 men with a wide range of body mass index (25.1 to 42.2 kg/m(2)). Isotopic enrichment of VLDL-apoB was measured using gas chromatography-mass spectrometry and a multicompartmental model used to estimate VLDL-apoB metabolic parameters. IPATM, RPATM, and SAATM (kilograms) were quantified between T11 and S1 using magnetic resonance imaging; TATM (kilograms) was determined using bioelectrical impedance. Insulin resistance was estimated by homeostasis model assessment (HOMA) score.
  
  
  RESULTS
  In stepwise regression, IPATM was the best predictor of hepatic secretion of VLDL-apoB (r = 0.390, p < 0.005) and TATM was the best predictor of VLDL-apoB fractional catabolic rate (r = 0.282, p < 0.05). IPATM remained significantly associated with VLDL-apoB secretion after adjusting for TATM or HOMA score (r = 0.360, p < 0.01 and r = 0.310, p < 0.05, respectively). This association was also independent of age, dietary intake, and body mass index. None of the fat compartments were significantly associated with the fractional catabolic rate of VLDL-apoB after adjusting for HOMA score.
  
  
  CONCLUSIONS
  In overweight/obese men, the quantity of both IPATM and TATM determine the kinetics of VLDL-apoB. The effect of IPATM on VLDL-apoB secretion is independent of both total fat mass and the degree of insulin resistance.
authors.affiliation: Department of Medicine, University of Western Australia, The Western Australian Institute for Medical Research, Perth, Australia. gfwatts@cyllene.uwa.edu.au
authors.forename: Gerald F
authors.initials: GF
authors.lastname: Watts
authors.forename: Dick C
authors.initials: DC
authors.lastname: Chan
authors.forename: P Hugh R
authors.initials: PH
authors.lastname: Barrett
authors.forename: Andrei V
authors.initials: AV
authors.lastname: Susekov
authors.forename: Jianmin
authors.initials: J
authors.lastname: Hua
authors.forename: Swithin
authors.initials: S
authors.lastname: Song
mesh_terms: D000273:Adipose Tissue; D000328:Adult; D053299:Apolipoprotein B-100; D001055:Apolipoproteins B / Q000097:blood / Q000378:metabolism*; D001786:Blood Glucose / Q000032:analysis; D001823:Body Composition; D002247:Carbon Isotopes; D003920:Diabetes Mellitus / Q000503:physiopathology; D004032:Diet; D017097:Electric Impedance; D005230:Fatty Acids, Nonesterified / Q000097:blood; D008401:Gas Chromatography-Mass Spectrometry; D018149:Glucose Intolerance / Q000503:physiopathology; D006706:Homeostasis; D006801:Humans; D007333:Insulin Resistance; D007700:Kinetics; D008079:Lipoproteins, VLDL / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000503:physiopathology*; D012044:Regression Analysis
chemical_list: D053299:Apolipoprotein B-100; D001055:Apolipoproteins B; D001786:Blood Glucose; D002247:Carbon Isotopes; D005230:Fatty Acids, Nonesterified; D008079:Lipoproteins, VLDL